Evidence for New Medical Products: Implications for Patients and Health Policy
What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy
This event is co-sponsored by the American Association for the Advancement of Science, the Division of Pharmacoepidemiology and Pharmacoeconomics of Brigham and Women’s Hospital/Harvard Medical School, and the National Center for Health Research.
Better implementation of evidence-based medicine can improve the quality and cost-effectiveness of health care in the U.S. This can be challenging in evaluating newly approved drugs and medical devices. While current law requires that medical products be proven safe and effective, there is growing pressure to expedite access to promising therapies and to lessen the research and regulatory requirements for manufacturers.
Unmet medical needs and patient demands call for a flexible approach to prescription drug and device regulation, but truncated premarket review may also lead to approval of products that are less effective than expected or have unanticipated safety problems. This groundbreaking conference will review the growing body of research on the medical and public health implications of medical product approval criteria, and examine these findings in the context of patient outcomes, costs, and health policy.
Please note that the video for Panel II has been temporarily removed for editing and will be reposted in mid-August.